{"product_id":"cris-ansoff-analysis","title":"(CRIS) Curis, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the Full Ansoff Matrix for Deeper Strategic Insight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Curis, Inc. Ansoff Matrix Analysis helps you quickly map the company’s growth options across market penetration, market development, product development, and diversification in a concise framework; the page includes a real preview\/sample so you can judge style and substance before buying. Purchase the full version to receive the complete, ready-to-use company-specific analysis for strategy, research, or investment work.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eErivedge advanced basal cell carcinoma focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eErivedge, Curis's co-developed, co-marketed oral hedgehog inhibitor, is the clearest market-penetration lever in advanced basal cell carcinoma. It has stayed in its approved use since FDA approval in 2012, so defending share here can extend current demand without new R\u0026amp;D risk. For Curis, even modest royalty flow from this niche can matter to a thin revenue base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche and Genentech commercial partnership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCuris, Inc.'s partnership with F. Hoffmann-La Roche Ltd. and Genentech Inc. gives Erivedge access to Roche's global oncology network, extending reach in the same approved basal cell carcinoma market. That matters because Erivedge was first approved by the U.S. FDA in 2012, so growth depends on deeper penetration more than new-market expansion. It also limits Curis's need to build a costly standalone sales force.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOral hedgehog pathway positioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eErivedge’s once-daily oral dosing and hedgehog-pathway blockade keep Curis anchored in advanced basal cell carcinoma, a niche where the drug already has FDA approval and long brand recall. That positioning helps defend share in an existing category while reinforcing physician and partner awareness. In a market where convenience and mechanism matter, oral use is a clear penetration edge.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eU.S. oncology market presence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCuris, Inc., headquartered in Lexington, Massachusetts, is focused on human cancers in the U.S., so its market sits inside a large, defined domestic oncology pool. The American Cancer Society projected 2.0 million new U.S. cancer cases and 618,120 deaths in 2025, showing the scale of the addressable market.\u003c\/p\u003e\n\u003cp\u003eThat gives Curis a clear base to defend and grow share, but its penetration remains tied to a narrow oncology niche and one commercial asset pathway.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2.0 million U.S. new cases in 2025\u003c\/li\u003e\n\u003cli\u003e618,120 U.S. cancer deaths in 2025\u003c\/li\u003e\n\u003cli\u003eDomestic focus supports share defense\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCurrent marketed asset leverage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCuris, Inc. uses Erivedge, its established oncology asset, as a market penetration tool because the drug keeps the company visible in the market and supports existing partner ties. Erivedge has been on the market since 2012, so it gives Curis a proven base to keep reaching the same oncology channels instead of starting from zero.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eErivedge is the core marketed asset.\u003c\/li\u003e\n\u003cli\u003e2012 launch supports long-term visibility.\u003c\/li\u003e\n\u003cli\u003eRoyalty income extends customer reach.\u003c\/li\u003e\n\u003cli\u003eClassic penetration uses current market reach.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCuris Bets on Erivedge to Defend Its Oncology Niche\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCuris’s market penetration rests on Erivedge, approved since 2012 and still used in advanced basal cell carcinoma, so growth comes from defending share in the same niche. The 2025 U.S. cancer load of 2.0 million new cases and 618,120 deaths shows the oncology pool is large, but Curis still depends on one mature asset. Roche and Genentech extend reach without Curis building its own sales force.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore asset\u003c\/td\u003e\n\u003ctd\u003eErivedge\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA approval\u003c\/td\u003e\n\u003ctd\u003e2012\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. cancer cases 2025\u003c\/td\u003e\n\u003ctd\u003e2.0 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes Curis, Inc.’s growth strategy through market penetration, market development, product development, and diversification options\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick Curis, Inc. Ansoff Matrix snapshot to simplify growth planning and reduce strategy gaps.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary, reputable sources that validate Curis, Inc. growth-path assumptions for fast, traceable Ansoff Matrix due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmavusertib hematologic expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEmavusertib widens Curis, Inc. from a basal cell carcinoma focus into hematologic oncology by testing one oral small-molecule platform in 3 settings: non-Hodgkin lymphomas, acute myeloid leukemia, and myelodysplastic syndromes. That is a clear Ansoff market-development move, since the company is taking existing science into new cancer markets. The prize is larger, but so is clinical risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFimepinostat DLBCL entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFimepinostat targets MYC-altered diffuse large B-cell lymphoma, a niche DLBCL subset that is often linked to aggressive disease; MYC alterations are reported in about 10% to 15% of DLBCL cases. This gives Curis a new market entry built on a targeted oncology mechanism, not a broad lymphoma play.\u003c\/p\u003e\n\u003cp\u003eThe move fits Ansoff's market development: the same drug platform, but a sharper patient group. In a U.S. DLBCL market with about 18,000 new cases a year, even a small biomarker-defined share can matter.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCA-170 solid tumor reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCA-170 broadens Curis, Inc. beyond advanced basal cell carcinoma by targeting advanced solid tumors and lymphomas, opening a market tied to about 20.0 million new cancer cases worldwide in 2022, with solid tumors making up roughly 90% of adult cancers. One oral asset can serve multiple oncology populations, which raises its reach and reuse across tumor types. This is classic market development: the same molecule, more cancer markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAurigene collaboration scope\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCuris, Inc.’s Aurigene Discovery Technologies Limited partnership is a partner-led route into adjacent immuno-oncology and precision oncology markets, extending Curis beyond its internal small-molecule footprint. It gives Curis access to external discovery capacity, shared development risk, and a wider shot at deal flow in oncology, where global spending topped hundreds of billions of dollars in 2025.\u003c\/p\u003e\n\u003cp\u003eThe scope matters for Ansoff because it is market development, not just product refinement: the same small-molecule platform is being pushed into new therapeutic segments and new commercial channels. In oncology, precision medicine now guides a growing share of late-stage programs, so the Aurigene tie-up can help Curis target niches with higher success odds and lower capital burn.\u003c\/p\u003e\n\u003cp\u003eThis kind of collaboration fits a low-fixed-cost expansion model, but it also makes partner execution critical because milestone timing, IP rights, and go\/no-go decisions sit outside Curis’ full control. For investors, the signal is clear: Curis is buying reach into larger adjacent markets without building every capability in-house.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMulti-indication oncology portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCuris, Inc. is using its oncology know-how across hematologic malignancies, solid tumors, and immuno-oncology, so this is market development rather than a new-product bet. The move opens more clinical and commercial segments while staying inside one therapeutic area. One platform, more cancer markets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHematologic, solid, and immune-oncology reach\u003c\/li\u003e\n\u003cli\u003eNew segments, same core capability set\u003c\/li\u003e\n\u003cli\u003eFits Ansoff market development\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCuris Expands Its Oncology Platform Into New Cancer Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCuris, Inc. is using the same oncology platform to enter new cancer markets, not new products: emavusertib in NHL, AML, and MDS; fimepinostat in MYC-altered DLBCL; and CA-170 in solid tumors and lymphomas. That is Ansoff market development, with reach expanding into cancer markets that total about 20.0 million new cases worldwide.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eNew market\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmavusertib\u003c\/td\u003e\n\u003ctd\u003eNHL, AML, MDS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFimepinostat\u003c\/td\u003e\n\u003ctd\u003eMYC-altered DLBCL\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCA-170\u003c\/td\u003e\n\u003ctd\u003eSolid tumors, lymphomas\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eCuris, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmavusertib Phase 1\/2\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEmavusertib is Curis, Inc.'s oral small-molecule lead in Phase 1\/2 studies, making it one of the company's key product-development programs. In Ansoff terms, it supports product development by adding a new oncology candidate to existing cancer markets. Curis reported $7.5 million in cash and cash equivalents at March 31, 2024, underscoring the need to advance programs efficiently.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCI-8993 VISTA antibody\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCI-8993 is Curis, Inc.'s one monoclonal antibody VISTA program, designed to block V-domain Ig suppressor of T cell activation and add a biologic path beside its small-molecule assets. In Ansoff terms, it supports product development by widening the oncology pipeline without changing the core market. That mix can improve research depth and reduce mechanism risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFimepinostat dual inhibition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFimepinostat is Curis, Inc.'s oral dual inhibitor of HDAC and PI3K, so it fits Ansoff's product development move by adding a new mechanism to the cancer pipeline. It is being developed for MYC-altered diffuse large B-cell lymphoma, a high-risk subset that accounts for about 10% to 15% of DLBCL cases. The dual-target design is meant to hit two cancer pathways in one drug, which may matter in a market where DLBCL still causes about 20,000 new U.S. cases a year.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCA-170 oral immuno-oncology candidate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCA-170 is Curis, Inc.'s oral small-molecule immuno-oncology candidate for advanced solid tumors and lymphomas, so it fits Ansoff product development: a new drug for the same cancer market. It broadens the oncology pipeline and supports Curis's oral-drug strategy, which can improve convenience versus infused therapies. As of Curis's latest public filings, CA-170 remains a pipeline asset, not a revenue driver.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eOral cancer asset\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eTargets solid tumors and lymphomas\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eExpands oncology pipeline\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eSupports oral strategy\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCA-327 pre-IND program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCA-327 is a pre-IND oncology asset, so advancing it is direct product development under the Ansoff Matrix. It shows Curis turning internal research into a new drug candidate, with no clinical data or revenue yet from this program. That means the value case is still early and tied to R\u0026amp;D execution, not sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePre-IND: earliest drug stage\u003c\/li\u003e\n\u003cli\u003eOne new oncology candidate\u003c\/li\u003e\n\u003cli\u003eZero clinical revenue so far\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCuris Builds Oncology Depth, But Cash and Data Still Drive the Story\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCuris, Inc. uses product development to push five oncology assets, with emavusertib, CI-8993, fimepinostat, CA-170, and CA-327 all aimed at existing cancer markets. The value is pipeline depth, but execution still hinges on early clinical data and cash control.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEmavusertib\u003c\/td\u003e\n\u003ctd\u003ePhase 1\/2\u003c\/td\u003e\n\u003ctd\u003eLead small molecule\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCA-327\u003c\/td\u003e\n\u003ctd\u003ePre-IND\u003c\/td\u003e\n\u003ctd\u003eNewest pipeline asset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHematologic and solid tumor spread\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCuris, Inc. spreads risk across at least 5 cancer areas, including non-Hodgkin lymphomas, AML, myelodysplastic syndromes, diffuse large B-cell lymphoma, and advanced solid tumors. That is broader than a single-indication bet and gives the pipeline more shots at clinical and commercial success. It also lets Curis address both hematologic and solid tumor markets, reaching more patient groups and prescribers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSmall molecules and antibody mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCuris, Inc. runs both oral small molecules and a monoclonal antibody, so it is not tied to one science platform. That mix lowers single-asset risk and lets the Company pursue biologic and small-molecule development at the same time, which is useful in oncology where oral drugs and antibodies often move on different timelines and success rates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmuno-oncology partnership channel\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Aurigene deal gives Curis, Inc. a second path to market through immuno-oncology and precision oncology, beyond its existing marketed asset. That is diversification in the Ansoff sense: it expands into new therapeutic areas and a new external collaboration model. The structure also spreads development risk across partnered compounds, milestone payments, and future royalties.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePre-IND oncology pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCA-327 is still pre-IND, so Curis, Inc. is only using early R\u0026amp;D to probe a market it does not serve today. That makes this a pure diversification move in the Ansoff Matrix: it targets a new product in a new market, with no clinical-stage sales yet. The key risk is long time to IND, since pre-IND assets carry the highest failure rate in biotech.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eCA-327 is not yet in human trials.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eNew-market entry sits at the R\u0026amp;D frontier.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eRevenue impact is still zero.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eExecution risk is highest before IND.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eFrom basal cell carcinoma to multi-cancer pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCuris, Inc. still leans on Erivedge in advanced basal cell carcinoma, but its pipeline now reaches beyond one tumor type, including hematologic and solid-tumor programs. That mix cuts dependence on a single commercial indication and fits an oncology diversification play. It also spreads risk across multiple assets and partnership paths.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne marketed anchor: Erivedge\u003c\/li\u003e\n\u003cli\u003eBroader pipeline: several cancers\u003c\/li\u003e\n\u003cli\u003eLower single-product risk\u003c\/li\u003e\n\u003cli\u003eMore shots at clinical value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCuris Spreads Oncology Risk Across Multiple Bets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCuris, Inc. uses diversification in oncology by spreading risk across multiple cancers, including NHL, AML, MDS, DLBCL, and advanced solid tumors. It also mixes oral small molecules, a monoclonal antibody, and partner-led programs, so one failure won’t define the Company. CA-327 adds a new-market, pre-IND bet, which raises risk but also broadens future upside.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eMix\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eErivedge\u003c\/td\u003e\n\u003ctd\u003eMarketed\u003c\/td\u003e\n\u003ctd\u003eAnchor asset\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCA-327\u003c\/td\u003e\n\u003ctd\u003ePre-IND\u003c\/td\u003e\n\u003ctd\u003eNew market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline\u003c\/td\u003e\n\u003ctd\u003eMulti-cancer\u003c\/td\u003e\n\u003ctd\u003e5+ indications\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234227069193,"sku":"cris-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/cris-ansoff-matrix.webp?v=1785715837","url":"https:\/\/dcfanalyst.com\/products\/cris-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}